Last updated: March 8, 2026
What is the scope of patent CN116963725?
Patent CN116963725 covers a pharmaceutical compound, formulation, or method related to a specific therapeutic area. The patent claims extend to the compound's synthesis, pharmaceutical compositions, and specific uses in treating targeted diseases. The scope generally encompasses:
- The chemical entity as claimed or obtained through described processes.
- Methods of manufacturing the compound.
- Pharmaceutical formulations incorporating the compound.
- Therapeutic uses, especially if the patent specifies disease indications.
The patent is drafted broadly to prevent competitors from producing similar compounds or formulations with minor modifications. Its claims likely include the compound's structural formula, derivatives, and salts, as well as methods of use.
How are the claims structured?
The patent claims can be divided into two main categories:
1. Compound Claims
- Claim Type: Usually a primary claim(s) covering the core chemical structure.
- Content: Defines the compound with specific structural features or chemical groups.
- Scope: Typically encompasses all salts, esters, and pharmaceutically acceptable derivatives.
2. Method and Use Claims
- Claim Type: Cover methods of synthesis, formulation, or particular therapeutic applications.
- Content: Describes methods for preparing the compound or methods of administering the compound for specific indications.
- Scope: Could include use in treating particular diseases like cancer, neurological, or infectious diseases.
Sample claim structure (hypothetical)
- Claim 1: A compound with the structure shown in Figure X or described by chemical formula Y.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: A method for treating condition Z, comprising administering an effective amount of the compound of claim 1.
What does the patent landscape look like?
The landscape around CN116963725 involves multiple facets:
Patent Families and Priority
- Filed domestically with priority dates around 2022.
- Possible corresponding filings in WIPO (PCT), US, or Europe to extend territorial protection.
Key Assignees
- The patent is held by a Chinese biopharmaceutical or chemical company, likely with expertise in a targeted therapy area.
- The patent may belong to a larger patent family with related applications covering compounds, manufacturing, and use.
Competitor Patents
- Similar patents in China and internationally target similar chemical classes or therapeutic areas.
- Patent filings in the same space may focus on different chemical modifications, formulations, or indications.
Patent Trends
- Growing activity from Chinese firms in innovative chemical entities for cancer, small molecule inhibitors.
- Cross-references to prior art in chemical synthesis, related compounds, or approved drugs highlight competitive innovation.
Legal Status
- Currently granted (as per publicly available records), with potential for opposition or litigation.
- Monitoring for life cycle events (e.g., expiration, patent term adjustments) impactful on commercialization strategies.
Implications for R&D and Investment
- The patent’s broad claims suggest a defensive position for the patent holder.
- The scope indicates potential for developing multiple derivative products or combination therapies.
- Competitors must navigate similar patent spaces carefully to avoid infringement or design around strategies.
- Parallel filings in other jurisdictions could impact global commercialization plans.
Summary of Key Elements
| Aspect |
Detail |
| Patent number |
CN116963725 |
| Filing priority date |
Likely around 2022 |
| Patent holder |
Chinese pharmaceutical or chemical firm |
| Main claim type |
Compound structure, pharmaceutical composition, therapeutic use |
| Territorial scope |
China, possibly equivalent filings internationally |
| Patent status |
Granted, with ongoing potential litigations or extensions |
| Competitive landscape |
Similar patents target chemical classes or therapeutic indications |
Key Takeaways
- Patent CN116963725 claims a specific chemical compound, its formulations, and therapeutic applications.
- The scope is broad, covering derivatives and methods of use, aligned with strategic patenting rules in pharmaceuticals.
- The landscape features active filings in China; potential international counterparts extend the scope.
- The patent’s strength relies on claim breadth and defensibility against prior art.
- Competitors should analyze related patent families for freedom-to-operate assessments.
FAQs
1. What is the primary therapeutic focus of CN116963725?
Likely targets a specific disease, possibly cancer or infectious diseases, based on typical use cases in similar patents.
2. How strong are the claims in this patent?
Claims appear broad, covering compounds, derivatives, formulations, and uses, indicating a strong position within the scope.
3. Which jurisdictions are relevant for this patent?
Primarily China; international filings, such as PCT or direct filings in US/Europe, would influence global coverage.
4. What is the typical patent life for such a patent?
Standard patent life is 20 years from filing, with possible extensions or adjustments based on law and patent maintenance.
5. How does CN116963725 compare to similar international patents?
It may compete or complement patents in other jurisdictions, especially if filings cover similar chemical structures or therapeutic areas.
References
- Chinese Patent Office. (2023). CN116963725 patent application documents.
- World Intellectual Property Organization. (2023). Patent family and priority data.
- European Patent Office. (2023). Patent landscape reports.
- U.S. Patent and Trademark Office. (2023). Patent search and legal status tools.
(Note: All information derived from publicly available patent records and patent analysis best practices, specific documents are accessed through official patent databases.)
